Entero Therapeutics, Inc. (NASDAQ:GRDX) Short Interest Up 470.4% in August

Entero Therapeutics, Inc. (NASDAQ:GRDX) was the target of a large growth in short interest in the month of August. As of August 14th, there was short interest totaling 118,986 shares, a growth of 470.4% from the July 30th total of 20,859 shares. Approximately 1.7% of the company’s shares are sold short. Based on an average daily trading volume, of 145,108 shares, the short-interest ratio is presently 0.8 days.

Entero Therapeutics Trading Down 0.7%

Shares of GRDX stock traded down $0.03 during mid-day trading on Thursday, reaching $4.01. The stock had a trading volume of 135,834 shares, compared to its average volume of 143,276. The stock’s 50-day moving average price is $3.78 and its two-hundred day moving average price is $3.42. Entero Therapeutics has a 52-week low of $1.73 and a 52-week high of $6.93. The firm has a market capitalization of $28.59 million, a PE ratio of -2.11 and a beta of 1.86.

Entero Therapeutics (NASDAQ:GRDX) last posted its earnings results on Wednesday, May 27th. The company reported ($0.82) earnings per share for the quarter. The firm had revenue of $0.04 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Entero Therapeutics stock. DRW Securities LLC purchased a new position in Entero Therapeutics, Inc. (NASDAQ:GRDX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 48,623 shares of the company’s stock, valued at approximately $227,000. DRW Securities LLC owned approximately 1.45% of Entero Therapeutics at the end of the most recent reporting period. 12.30% of the stock is owned by hedge funds and other institutional investors.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.